4.3 Article

A new era in the management of psoriasis? The biologics: facts and controversies

Journal

CLINICS IN DERMATOLOGY
Volume 28, Issue 1, Pages 81-87

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.clindermatol.2009.03.002

Keywords

-

Categories

Funding

  1. Merke-Serono
  2. Wyeth
  3. Abbott
  4. Schering-Plough
  5. Janssen-Cilag

Ask authors/readers for more resources

During the last 30 years, the tremendous progress in our knowledge of the pathogenesis of psoriasis has led to the development of new agents, the so-called biologics, that have revolutionized the management of severe psoriasis. Dermatologists and patients see this emerging therapy as a new perspective in the state of the art in managing moderate to severe psoriasis. After a few years of use in daily practice, we may begin to analyze the power of the currently available biologic agents in the management of severe psoriasis from the perspective of facts. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available